Search results for "25"

showing 10 items of 3263 documents

Gene Amplification-Associated Overexpression of the Selenoprotein tRNA Enzyme TRIT1 Confers Sensitivity to Arsenic Trioxide in Small-Cell Lung Cancer

2021

Simple Summary Small-cell lung cancer accounts for approximately 13% of all new lung cancer diagnoses, but in contrast to non-small-cell lung cancer, the implementation of targeted treatments in small-cell lung cancer has been limited, with little improvement in the clinical outcome in the last several decades. Exploring new pathways for targeted therapy, we have observed that extra-copies of the tRNA modifier TRIT1, involved in the translation of selenoproteins, confers sensitivity to arsenic trioxide in small-cell lung cancer. This finding could open a new therapeutic niche for a tumor type with such a dismal clinical course. The alteration of RNA modification patterns is emerging as a co…

Cancer Researchgene amplificationCellTRIT1lcsh:RC254-282Articlechemistry.chemical_compoundRNA modificationsGene duplicationmedicinesmall-cell lung cancerArsenic trioxideGenechemistry.chemical_classificationSelenocysteineChemistryRNAlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstransfer RNACell biologymedicine.anatomical_structureOncologyTransfer RNAselenoproteinsCàncer de pulmóRNASelenoproteinLung cancer
researchProduct

The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.

2021

The prevalence of primary liver cancer is rapidly rising all around the world. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Unfortunately, the traditional treatment methods to cure HCC showed poor efficacy in patients who are not candidates for liver transplantation. Until recently, tyrosine kinase inhibitors (TKIs) were the front-line treatment for unresectable liver cancer. However, rapidly emerging new data has drastically changed the landscape of HCC treatment. The combination treatment of atezolizumab plus bevacizumab (immunotherapy plus anti-VEGF) was shown to provide superior outcomes and has become the new standard first-line treatment for unresect…

Cancer Researchhepatocellular carcinoma (HCC)clinical trialsOncologyliver cancer (LC)Mini ReviewNeoplasms. Tumors. Oncology. Including cancer and carcinogensimmunotherapyimmune checkpoint blockadeRC254-282Frontiers in oncology
researchProduct

Indocyanine Green to Assess Vascularity of Ileal Conduit Anastomosis During Pelvic Exenteration for Recurrent/Persistent Gynecological Cancer: A Pilo…

2021

IntroductionPelvic exenteration performed for recurrent/persistent gynecological malignancies has been associated with urological short- and long-term morbidity due to altered vascularization of tissues for previous radiotherapy. The aims of the present study were to describe the use of intravenous indocyanine green (ICG) to assess vascularity of urinary diversion (UD) after pelvic exenteration for gynecologic cancers, to evaluate the feasibility and safety of this technique, and to assess the postoperative complications.MethodsProspective, observational, single-center, pilot study including consecutive patients undergoing anterior or total pelvic exenteration due to persistent/recurrent gy…

Cancer Researchmajor postoperative complicationsNeoplasms. Tumors. Oncology. Including cancer and carcinogensanastomosisgynecological canceranastomosimajor postoperative complicationeye diseasespelvic exenteration (PE)body regionsileal conduit diversionSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyindocyanine green (ICG)anastomosis; gynecological cancer; ileal conduit diversion; indocyanine green (ICG); major postoperative complications; pelvic exenteration (PE)RC254-282Original ResearchFrontiers in Oncology
researchProduct

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

2020

BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.MethodsThis randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS.ResultsAt a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 mont…

Cancer Researchmedicine.medical_specialty2435[SDV]Life Sciences [q-bio]ImmunologyMedizinIpilimumabrandomized trialsGastroenterologyAsymptomaticlaw.inventionimmunology03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineClinical endpointImmunology and Allergy1506030212 general & internal medicineAdverse effectRC254-282Clinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryIncidence (epidemiology)MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseimmunology; oncology; randomized trials[SDV] Life Sciences [q-bio]Oncology030220 oncology & carcinogenesisoncologyMolecular Medicinemedicine.symptombusinessBrain metastasismedicine.drug
researchProduct

The Porto European Cancer Research Summit 2021.

2021

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…

Cancer Researchmedicine.medical_specialty:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]infrastructures for translational cancer researchDeclarationTranslational researchContext (language use)comprehensive cancer centresMeeting Reportclinical/prevention trials:profesiones sanitarias::medicina::medicina clínica::medicina de precisión [DISCIPLINAS Y OCUPACIONES]Translational Research Biomedicaloutcomes research:neoplasias [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]cancer research/care/prevention continuumNeoplasmsPolitical scienceGeneticsmedicineHumansmedia_common.cataloged_instance:Health Occupations::Medicine::Clinical Medicine::Precision Medicine [DISCIPLINES AND OCCUPATIONS]Medicina personalitzadaPrecision MedicineEuropean unionRC254-282media_commongeographySummitgeography.geographical_feature_categoryHealth economics:Natural Science Disciplines::Science::Research::Biomedical Research [DISCIPLINES AND OCCUPATIONS]Neoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineCancer MissionEuropescience policy:Neoplasms [DISEASES]Medicina - InvestigacióOncologyQuality of LifeCancer researchMolecular MedicineScience policyCàncer - PrevencióOutcomes research:disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica [DISCIPLINAS Y OCUPACIONES]
researchProduct

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Dou…

2021

BackgroundFew data regarding post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC) are available.MethodsThis multicenter, retrospective study aimed at evaluating clinicians’ attitude, and the safety and effectiveness of post-induction strategies in consecutive patients affected by left-sided RAS/BRAF wild-type mCRC treated with doublet chemotherapy plus anti-EGFR as first-line regimen, who did not experience disease progression within 6 months from induction initiation, at 21 Italian and 1 Spanish Institutions. The measured clinical outcomes were: p…

Cancer Researchmedicine.medical_specialtyColorectal cancerPopulationGastroenterologymaintenanceFOLFIRIFOLFOXInternal medicinecetuximabmedicineAdverse effecteducationRC254-282education.field_of_studybusiness.industryMCRCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studymedicine.diseaseRegimenFOLFOXOncologyCohortFOLFIRIbusinesspanitumumabmedicine.drugFrontiers in Oncology
researchProduct

SuperHistopath: A Deep Learning Pipeline for Mapping Tumor Heterogeneity on Low-Resolution Whole-Slide Digital Histopathology Images.

2021

High computational cost associated with digital pathology image analysis approaches is a challenge towards their translation in routine pathology clinic. Here, we propose a computationally efficient framework (SuperHistopath), designed to map global context features reflecting the rich tumor morphological heterogeneity. SuperHistopath efficiently combines i) a segmentation approach using the linear iterative clustering (SLIC) superpixels algorithm applied directly on the whole-slide images at low resolution (5x magnification) to adhere to region boundaries and form homogeneous spatial units at tissue-level, followed by ii) classification of superpixels using a convolution neural network (CN…

Cancer Researchmedicine.medical_specialtyComputer scienceMagnificationContext (language use)lcsh:RC254-282Convolutional neural network030218 nuclear medicine & medical imaging03 medical and health sciencesneuroblastoma0302 clinical medicinebreast cancermedicinemelanomatumor region classificationSegmentationCluster analysisOriginal Researchbusiness.industryDeep learningDigital pathologydeep learningPattern recognitionlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmachine learningOncology030220 oncology & carcinogenesisHistopathologyArtificial intelligencebusinessdigital pathologycomputational pathologyFrontiers in oncology
researchProduct

Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection

2021

Background: Hepatic resection remains the treatment of choice for patients with early-stage HCC with preserved liver function. Unfortunately, however, the majority of patients develop tumor recurrence. While several clinical factors were found to be associated with tumor recurrence, HCC pathogenesis is a complex process of accumulation of somatic genomic alterations, which leads to a huge molecular heterogeneity that has not been completely understood. The aim of this study is to complement potentially predictive clinical and pathological factors with next-generation sequencing genomic profiling and loss of heterozygosity analysis. Methods: 124 HCC patients, who underwent a primary hepatic …

Cancer Researchmedicine.medical_specialtyHepatitis C virusSubgroup analysisLower riskmedicine.disease_causelcsh:RC254-282GastroenterologyArticlePathogenesisLoss of heterozygositynext-generation sequencing.03 medical and health sciences0302 clinical medicineInternal medicineMedicinePTENHCCHCC recurrencebiologybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinomaliver resectionbiology.proteinnext-generation sequencingloss of heterozygosity030211 gastroenterology & hepatologyLiver functionbusinessCancers
researchProduct

Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients

2021

Purpose: We aimed at assessing the impact of surveillance on long-term survival in HCC patients. Methods: From the ITA.LI.CA database, we selected 1028 cases with long (≥5 years, LS group) and 2721 controls with short-term survival (&lt

Cancer Researchmedicine.medical_specialtyHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIACancer stageIndependent predictorLogistic regressionlcsh:RC254-282Article03 medical and health sciencesLong-term survival0302 clinical medicineInternal medicineLong term survivalmedicineTreatment.Surveillancebusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNAConfoundingmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensTreatmentCancer stage; Hepatocellular carcinoma; Long-term survival; Surveillance; TreatmentOncology030220 oncology & carcinogenesisHepatocellular carcinomaBaseline characteristics030211 gastroenterology & hepatologybusiness
researchProduct

Identification of High-Risk Atypical Meningiomas According to Semantic and Radiomic Features

2020

Up to 60% of atypical meningiomas (World Health Organization (WHO) grade II) reoccur within 5 years after resection. However, no clear radiological criteria exist to identify tumors with higher risk of relapse. In this study, we aimed to assess the association of certain radiomic and semantic features of atypical meningiomas in MRI with tumor recurrence. We identified patients operated on primary atypical meningiomas in our department from 2007 to 2017. An analysis of 13 quantitatively defined radiomic and 11 qualitatively defined semantic criteria was performed based on preoperative MRI scans. Imaging characteristics were assessed along with clinical and survival data. The analysis include…

Cancer Researchmedicine.medical_specialtyMultivariate analysisTumor resectionlcsh:RC254-282survivalArticleWorld healthResection03 medical and health sciences0302 clinical medicineatypical meningiomamedicineUnivariate analysisbusiness.industryHazard ratiopredictionOdds ratiolcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalOncologyradiomics030220 oncology & carcinogenesisRadiologybusiness030217 neurology & neurosurgeryCancers
researchProduct